Company: RNAC
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001453687-25-000099
Chunk: 86

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part II, Item 1A
Chunk 86
---
Item 1A.  Risk Factors 

See the risk factors previously disclosed in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024. There have been no material changes from the risk factors previously disclosed in such filings.

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds

Not applicable.

Item 3.  Defaults Upon Senior Securities

None.

Item 4.  Mine Safety Disclosures

None.

Item 5.  Other Information

On May 15, 2025, Milos Miljkovic, our Chief Medical Officer, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Dr. Miljkovic’s plan provides for the exercise of vested stock options and the potential associated sale of up to 30,528 shares of our common stock and the potential sale of up to an additional 2,689 shares of our common stock until and including March 31, 2026. The foregoing exercises or sales, if any, will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and March 31, 2026.

Other than as set forth above, during the fiscal quarter ended June 30, 2025, no officer or director, as defined in Rule 16a-1(f) of the Exchange Act, informed us of the adoption, modification or termination of any “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K .

41

Table of Contents

Item 6.  Exhibits

EXHIBIT INDEX

  Incorporated by ReferenceExhibitNumberExhibit DescriptionFormFile No.ExhibitFilingDate2.1*Agreement and Plan of Merger, dated November 13, 2023, by and among Selecta Biosciences, Inc., Sakura Merger Sub I, Inc., Sakura Merger Sub II, LLC, and Cartesian Therapeutics, Inc.8-K001-377982.111/13/20233.1(a)Restated Certificate of Incorporation of Selecta Biosciences, Inc.8-K001-377983.16/29/20163.1(b)Certificate of Amendment to the Restated